Saxagliptin (Onglyza, Kombiglyze XR) and alogliptin (Nesina, Kazano, Oseni) are part of the class of dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, which are used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
The FDA announced that as a result of the findings, it will be adding new warnings to the labels on all saxagliptin- and alogliptin- containing medications.
The findings are from an FDA evaluation of two large clinical trials conducted in patients with heart disease. Each trial showed that more patients were hospitalized for heart failure who received saxagliptin- or alogliptin-containing medicines compared to patients who received placebo.
READ MORE Type 2 Diabetes Medication LEGAL NEWS
In the alogliptin trial, 3.9% of alogliptin-treated patients were hospitalized for heart failure versus 3.3% in the placebo group, which translates to 39 out of every 1,000 patients compared to 33 out of every 1,000 patients, respectively.
In addition to adding warnings to these medication labels, the FDA is recommending that health care professionals consider discontinuing medications containing saxagliptin and alogliptin in patients who develop heart failure and monitor their diabetes control.